



Biotech Daily

Wednesday August 21, 2019

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH DOWN: IMUGENE UP 10%; ALTERITY DOWN 7%**
- * **SOMNOMED REVENUE UP 12% TO \$59m, LOSS UP 91% TO \$16.4m**
- * **MEDICAL DEVEL REVENUE UP 19% TO \$21m, PROFIT UP 327% TO \$1m**
- * **IMPEDIMED REVENUE UP 25% TO \$4.2m, LOSS DOWN 12% TO \$24m**
- * **MGC RAISES \$4.75m, PLAN FOR \$1m MORE, TO LIST ON LSE**
- * **CANN GLOBAL (QLD BAUXITE) RAISES \$5.95m, RETURN TO ASX**
- * **SLOAN KETTERING APPROVES OPTISCAN MICROSCOPE FOR TRIAL**
- * **NOXOPHARM: NOX66 'ABSCOPAL' RESPONSE IN MICE**
- * **CHAIR DR BILL GARNER DILUTED TO 17% OF RACE**

MARKET REPORT

The Australian stock market fell 0.94 percent on Wednesday August 21, with the ASX200 down 61.7 points to 6,483.3 points.

Fifteen of the Biotech Daily Top 40 stocks were up, 17 fell and eight traded unchanged.

Imugene was the best, up 0.2 cents or 10 percent to 2.2 cents, with 11.2 million shares traded.

Actinogen climbed 5.9 percent; Medical Developments, Optiscan and Telix improved more than four percent; Antisense was up 3.9 percent; Clinuvel, Ellex, Patrys and Universal Biosensors rose more than two percent; Polynovo, Proteomics and Volpara were up one percent or more; with Compumedics, CSL and Cynata up by less than one percent.

Alterity (Prana) led the falls, down 0.2 cents or 6.9 percent to 2.7 cents, with 30,000 shares traded, followed by Amplia (Innate) down 6.5 percent to 7.2 cents with 256,250 shares traded.

Paradigm fell 4.4 percent; LBT and Opthea lost three percent or more; Immutep, Kazia, Neuren, Pharmaxis, Prescient and Pro Medicus shed more than two percent; Avita, Cochlear, Oncosil and Orthocell were down more than one percent; with Mesoblast, Nanosonics, Next Science and Resmed down by less than one percent.

SOMNOMED

Somnomed says revenue for the year to June 30, 2019 was up 12.4 percent to \$58,892,033, with net loss after tax up 90.7 percent to \$16,437,667.

Somnomed said revenue from its Somnodent oral appliances for obstructive sleep apnoea was up 13 percent in Europe and 16 percent in the Asia Pacific.

The company said the increased loss was due to the closure of the Renew Seep Solutions business in the period to December 31, 2018.

Somnomed said that net tangible asset backing per share fell 70.5 percent to 10.53 cents for the year to June 30, 2019, diluted loss per share increased 82.5 percent to 28.28 cents and it had cash and cash equivalents of \$7,697,054 at June 30, 2019 compared to \$13,383,389 at June 30, 2018.

Somnomed fell 15 cents or 7.5 percent to \$1.85.

MEDICAL DEVELOPMENTS INTERNATIONAL

Medical Developments says revenue for the year to June 30, 2019 was up 19.3 percent to \$21,382,000, with net profit after tax up 327.2 percent to \$1,038,000.

Medical Developments said that sales of its Pentrox inhaled methoxyflurane analgesic were up 47 percent globally, 401 percent in Europe, 68 percent in the UK and 38 percent to Australian Ambulance, while revenue from its respiratory devices, primarily asthma spacers, fell five percent.

The company said it would pay a fully-franked dividend of 2.0 cents for holders at the record date of September 4, 2019 to be paid on October 4, 2019.

Medical Developments said that net tangible asset backing per share was positive 5.6 cents compared to negative 17.9 cents for the previous corresponding period.

The company said that basic earnings per share was up 292.7 percent to 1.61 cents and it had cash and cash equivalents of \$25,620,000 at June 30, 2019, compared to \$794,000 at June 30, 2018.

Medical Developments was up 21 cents or 4.4 percent to \$4.97.

IMPEDIMED

Impedimed says revenue for the year to June 30, 2019 was up 25.3 percent to \$4,156,000 with a net loss after tax down 11.9 percent to \$24,123,000.

Last year, Impedimed reported revenue of \$5,225,000 and Biotech Daily calculates this year's revenue fell \$1,069,000 or 20.5 percent.

The company said revenue from Sozo sales and services was up 228.6 percent to \$2.3 million along with "legacy revenue" down 30.8 percent to \$1.8 million and the \$US500,000 (\$A702,007) sale of its subsidiary Xitron Technologies to Vitrek LLC (BD: Oct 12, 2018).

Impedimed said that "certain prior year amounts have been reclassified for consistency with the current reporting period presentation".

The company said that diluted and basic loss per share was down 14.3 percent to six cents, net tangible assets per share fell 66.7 percent to 3.0 cents and it had cash and cash equivalents of \$11,330,000 million at June 30, 2019 compared to \$31,345,000 at June 30, 2018.

Impedimed was unchanged at 13 cents.

MGC PHARMACEUTICALS

MGC says it has raised \$4.75 million in a placement at four cents a share and hopes to raise a further \$1 million in a share plan to list on the London Stock Exchange.

MGC said the four cents price was a 25 percent discount to the 30-day volume weighted average price of 5.38 cents prior to Monday's trading halt (BD: Aug 19, 2019).

The company said Merchant Corporate Advisory and Chieftain Securities were joint lead managers to the placement and would receive six percent of total funds raised and 9,000,000 options in three tranches of 3,000,000 options exercisable at five, six and seven cents a share by August 31, 2023.

MGC said that executive chairman Brett Mitchell was a director and shareholder of Chieftain.

The company said it had appointed Cannacord Genuity as its equity capital markets advisor to lead its planned dual listing on the London Stock Exchange by 2020 and Cannacord would receive three tranches of 14,500,000 options exercisable at five, six and seven cents a share within four years of the issue date.

MGC said the record date for the share plan was August 28, 2019.

MGC said the funds raised would be used for its ongoing operations to produce and sell pharmaceutical grade cannabinoid derived medicines, for initial construction of its Malta marijuana facility and for costs towards a dual listing.

MGC fell half a cent or 10 percent to 4.5 cents with 5.4 million shares traded.

CANN GLOBAL (FORMERLY QUEENSLAND BAUXITE)

Cann Global says it has raised \$5.95 million at 3.5 cents a share and will be reinstated on the ASX.

Cann Global managing director Sholom Feldman told Biotech Daily that the company would be reinstated on August 23, 2019.

The company said that one option would be issued for every two new shares subscribed in the placement, exercisable at 10 cents each by April 30, 2020.

Cann Global was in an extended suspension and last traded at 3.7 cents.

OPTISCAN IMAGING

Optiscan says its confocal laser endo-microscope has been approved for an oral cancer trial at New York's Sloan Kettering Cancer Centre.

Optiscan said that a pre-requisite for use of its microscope at Sloan Kettering was third-party validation that its covering sheath could be sterilized for up to 10 cycles in an autoclave machine.

The company said it expected to begin imaging "in the near term" and would seek further approvals for the microscope to be used in cervical cancer and oesophageal cancer trials

Optiscan was up 0.2 cents or 4.65 percent to 4.5 cents.

NOXOPHARM

Noxopharm says preclinical studies of NOX66, or Veyonda, with radiotherapy in mice have shown an "abscopal" response.

Noxopharm said the studies showed an anti-cancer response in the irradiated tumors as well as tumors elsewhere in the body.

Noxopharm fell one cent or 2.5 percent to 39 cents with 1.2 million shares traded.

RACE ONCOLOGY

Race chairman Dr William Garner says his 16,414,927 share-holding has been diluted from 18.82 percent to 17.15 percent.

The San Juan, Puerto Rico-based Dr Garner said that he was diluted in yesterday's \$1.45 million placement at 6.6 cents a share (BD: Aug 20, 2019).

Race fell 0.1 cents or 1.2 percent to 8.3 cents with 1.5 million shares traded.